Johnson & Johnson sells LifeScan, a blood glucose monitoring solutions provider. Credit: Open Grid Scheduler/Grid Engine.

Johnson & Johnson (J&J) has completed the sale of its subsidiary LifeScan to private investment firm Platinum Equity for a total consideration of around $2.1bn.

LifeScan offers blood glucose monitoring products such as personal blood glucose meters, testing strips, lancets, point-of-care testing devices and integrated digital solutions under the OneTouch brand.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The business reaches nearly 20 million patients across more than 90 countries. Last year, it generated approximately $1.5bn in net revenues.

“LifeScan offers blood glucose monitoring products such as personal blood glucose meters, testing strips, lancets, point-of-care testing devices and integrated digital solutions under the OneTouch brand.”

J&J noted that following the divestiture it will cater to the needs of diabetes patients via other products, services and solutions in its Medical Device, Pharmaceuticals and Consumer businesses.

This is said to include innovation in various fields, including bariatric surgery, and drugs such as Invokana (canagliflozin) and Invokamet (canagliflozin/metformin HCl).

LifeScan president and CEO Val Asbury said: “We are excited for our future and what we can accomplish with the addition of Platinum Equity’s financial and operational resources.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“We share an unwavering commitment to patient care and know there is tremendous opportunity for LifeScan to grow and evolve. With LifeScan’s talent and capabilities, our iconic OneTouch brand, and Platinum’s support, there’s no limit to what we can achieve.”

The blood glucose monitoring business will now operate as a standalone entity with a new corporate logo and brand identity.

Platinum Equity Partner Jacob Kotzubei said that it will support LifeScan in improving the quality of life for people with diabetes.

The private investment firm proposed a binding offer to acquire LifeScan in March this year. J&J accepted the proposal in June, after consultation with relevant works councils and trade unions.